Recent blog posts
Intravacc reveals encouraging initial human trial results for its novel OMV nasal spray vaccine against COVID-19
Latest Hotspot
3 min read
Intravacc reveals encouraging initial human trial results for its novel OMV nasal spray vaccine against COVID-19
29 March 2024
Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10.
Read →
AST-201: Aptamer Sciences' Novel Therapy for Liver Cancer in NDA Submission
Latest Hotspot
4 min read
AST-201: Aptamer Sciences' Novel Therapy for Liver Cancer in NDA Submission
29 March 2024
Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.
Read →
Novo Nordisk plans to purchase Cardior Pharmaceuticals, bolstering its portfolio in heart health management
Latest Hotspot
3 min read
Novo Nordisk plans to purchase Cardior Pharmaceuticals, bolstering its portfolio in heart health management
29 March 2024
Novo Nordisk has entered into an acquisition agreement with Cardior Pharmaceuticals, with the deal amounting to a maximum of 1.025 billion Euros.
Read →
Apogee Therapeutics Begins Phase 1 Trial of APG808 for COPD and Inflammation
Latest Hotspot
3 min read
Apogee Therapeutics Begins Phase 1 Trial of APG808 for COPD and Inflammation
29 March 2024
Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.
Read →
Regeneron Announces Progress on Licensing Submission for Cancer Drug Odronextamab
Latest Hotspot
3 min read
Regeneron Announces Progress on Licensing Submission for Cancer Drug Odronextamab
29 March 2024
Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.
Read →
Rhythm Pharma Begins Human Trials for Weekly MC4R-Targeting Drug RM-718
Latest Hotspot
3 min read
Rhythm Pharma Begins Human Trials for Weekly MC4R-Targeting Drug RM-718
29 March 2024
Rhythm Pharma Initiates First Human Dosing in Early-Stage Study of RM-718, a Once-Weekly Compound Targeting MC4R Receptors.
Read →
FDA Approves Bio-Thera's Phase II Trial of Novel ADC BAT8006
Latest Hotspot
3 min read
FDA Approves Bio-Thera's Phase II Trial of Novel ADC BAT8006
29 March 2024
US FDA grants Bio-Thera Solutions approval to start Phase II trial of BAT8006, a novel ADC aimed at Folate Receptor alpha.
Read →
AbbVie's Acquisition of Landos Biopharma Bolsters Inflammatory and Autoimmune Treatment Portfolio
Latest Hotspot
3 min read
AbbVie's Acquisition of Landos Biopharma Bolsters Inflammatory and Autoimmune Treatment Portfolio
29 March 2024
AbbVie Plans to Take Over Landos Biopharma, Enhancing Its Collection of Treatments for Inflammation and Autoimmunity.
Read →
Ferrer and Verge Genomics Partner to Advance ALS Experimental Treatment VRG50635 to Clinical Trials
Latest Hotspot
3 min read
Ferrer and Verge Genomics Partner to Advance ALS Experimental Treatment VRG50635 to Clinical Trials
28 March 2024
Ferrer and Verge Genomics have entered into a collaboration to jointly advance the experimental treatment for ALS, designated as VRG50635, into clinical trials.
Read →
Astria Therapeutics Reports Promising ALPHA-STAR Phase 1b/2 Results for HAE Using STAR-0215
Latest Hotspot
3 min read
Astria Therapeutics Reports Promising ALPHA-STAR Phase 1b/2 Results for HAE Using STAR-0215
28 March 2024
Astria Therapeutics Reveals Encouraging Early Findings in ALPHA-STAR Phase 1b/2 Study for HAE with STAR-0215.
Read →
Ultomiris Approved by US to Treat Adults with NMOSD
Latest Hotspot
3 min read
Ultomiris Approved by US to Treat Adults with NMOSD
28 March 2024
Ultomiris receives US green light to treat adult patients with spectrum disorder related to neuromyelitis optica (NMOSD).
Read →
FDA Approves OPSYNVI® as First Daily Combo Therapy for PAH
Latest Hotspot
3 min read
FDA Approves OPSYNVI® as First Daily Combo Therapy for PAH
27 March 2024
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).
Read →